Trevogrumab

Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as myostatin) . Trevogrumab is used in research on muscle wasting conditions, including disuse atrophy, chronic diseases, and changes in food and nutrient intake[1][2][3].

Product Specifications

CAS Number

[1429201-24-0]

Product Name Alternative

REGN-1033

UNSPSC

12352203

Target

TGF-beta/Smad

Type

Inhibitory Antibodies

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/trevogrumab.html

Purity

99.77

Solubility

10 mM in DMSO

Smiles

[Trevogrumab]

Molecular Weight

(144.04 kDa)

References & Citations

[1]Masakazu Saitoh, et al. Myostatin inhibitors as pharmacological treatment for muscle wasting and muscular dystrophy. Volume2, Issue1, January 2017, Pages 1-10|[2]Mitra A, et al. The elusive role of myostatin signaling for muscle regeneration and maintenance of muscle and bone homeostasis. Osteoporos Sarcopenia. 2023 Mar;9 (1) :1-7.|[3]Latres E, et al. Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet Muscle. 2015 Oct 9;5:34.